
Sellas Vaccine Extends Blood Cancer Patient Survival
Sellas Life Sciences reported its experimental vaccine significantly extended survival in a late stage blood cancer trial. The treatment reduced the risk of death by forty one percent compared to standard care. The company plans to pursue expedited US regulatory approval in the coming year.
Xurve View
Insights:
Xurve View

SELLAS LIFE SCIENCES GROUP I extended overall survival by 41% in a late-stage blood cancer trial, lifting its shares more than threefold to $22.93 on Tuesday afternoon. The experimental vaccine, known as GPS, targets acute myeloid leukemia patients in remission who cannot receive bone marrow transplants. The treatment added 9.3 months of median survival compared to standard care, offering a new therapeutic option for aggressive blood cancers.










